You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

Please do not respond to this message.

The Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection have been updated. 

The Pediatric Guidelines, developed by the Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, now include Supplement II, titled "Managing Complications of HIV Infection in HIV-Infected Children on Antiretroviral Therapy, "and Supplement III, titled "Adverse Drug Effects."  Also included in the new version are updates to the atazanavir, indinavir, and enfuvirtide sections in Supplement I, "Pediatric Antiretroviral Drug Information."

All new information is highlighted in yellow in the main document.  Supplements II and III are new to the guidelines and are highlighted in title only.  

The updated guidelines document is available in the Pediatric Guidelines section (http://aidsinfo.nih.gov/guidelines/default_db2.asp?id=51) of the Guidelines page on the AIDSinfo  Web site.

Richard Klein
HIV/AIDS Program Director
Office of Special Health Issues
Food and Drug Administration

To UNSUBSCRIBE from this list, or change your e-mail address, please go to
http://list.nih.gov/cgi-bin/wa?SUBED1=fda-hiv-aids&A=1